Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-02-24 @ 1:25 PM
Study NCT ID:
NCT04928105
Status:
UNKNOWN
Last Update Posted:
2022-05-31
First Post:
2021-06-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
Sponsor:
Hebei Senlang Biotechnology Inc., Ltd.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma, T-Cell | View |
Keywords: